News of the WeekScienceInsider

From the Science Policy Blog

See allHide authors and affiliations

Science  02 Apr 2010:
Vol. 328, Issue 5974, pp. 25
DOI: 10.1126/science.328.5974.25-b

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

ScienceInsider reported this week that the most controversial patents in biotechnology—covering breast cancer genes BRCA1 and BRCA2—were declared invalid this week by a U.S. district court, among other stories.